GenMark Diagnostics (GNMK) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	GenMark Diagnostics, Inc.
Entity Central Index Key	1487371
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		42,138,925

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets
Cash and cash equivalents	$36,913	$36,855
Marketable Securities	34,041	33,651
Accounts receivable - net of allowances of $2,702 and $2,702, respectively	4,444	4,889
Inventories	2,148	2,137
Prepaid expenses and other current assets	770	575
Total current assets	78,316	78,107
Property and equipment, net	11,354	11,052
Intangible assets, net	1,806	1,870
Restricted cash	758	758
Other long-term assets	115	183
Total assets	92,349	91,970
Current liabilities
Accounts payable	3,390	3,468
Accrued compensation	3,388	5,172
Other current liabilities	2,832	3,653
Total current liabilities	9,610	12,293
Deferred Rent Credit, Noncurrent	1,402	1,445
Long-term liabilities
Deferred rent	9,502	0
Other non-current liabilities	249	208
Total liabilities	20,763	13,946
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000 authorized, none issued	0	0
Common stock, $0.0001 par value; 100,000 authorized; 42,128 and 41,859 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	4	4
Additional paid-in capital	343,925	340,502
Accumulated deficit	-272,341	-262,472
Accumulated other comprehensive loss	-2	-10
Total stockholders’ equity	71,586	78,024
Total liabilities and stockholders’ equity	$92,349	$91,970

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable - net of allowance	$2,702	$2,702
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	42,128,000	41,859,000
Common stock, outstanding	42,128,000	41,859,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		$0
Revenue
Product revenue	10,012	7,866
License and other revenue	95	47
Total revenue	10,107	7,913
Cost of revenue	3,991	3,591
Gross profit	6,116	4,322
Operating expenses
Sales and marketing	3,693	2,979
General and administrative	3,671	2,933
Research and development	8,779	7,270
Total operating expenses	16,143	13,182
Loss from operations	-10,027	-8,860
Other income (expense)
Interest income	36	86
Interest expense	-73	-1
Other income (expense)	217	-2
Total other income (expense)	180	83
Loss before provision for income taxes	-9,847	-8,777
Provision for income taxes	-22	-6
Net loss	-9,869	-8,783
Net loss per share, basic and diluted	($0.24)	($0.21)
Weighted average number of shares outstanding, basic and diluted	41,774	41,079
Other comprehensive loss
Net loss	-9,869	-8,783
Net unrealized gains (losses) on available-for-sale investments, net of tax	-17	12
Comprehensive loss	($9,877)	($8,771)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
Payments of Debt Issuance Costs	($700)	$0
Operating activities
Net loss	-9,869	-8,783
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	797	574
Amortization of premiums on investments	73	198
Amortization of Financing Costs and Discounts	49	0
Gain (Loss) on Sale of Other Investments	-223	0
Stock-based compensation	2,339	1,389
Non-cash inventory adjustments	402	219
Other Operating Activities, Cash Flow Statement	20	0
Changes in operating assets and liabilities:
Accounts receivable	445	283
Inventories	-366	169
Prepaid expenses and other assets	-216	107
Accounts payable	-775	-449
Accrued compensation	-919	10
Other liabilities	-22	-101
Net cash used in operating activities	-8,265	-6,384
Investing activities
Purchase of available-for-sale securities	-14,797	-13,039
Payments for intellectual property licenses	-550	0
Purchases of property and equipment	-411	-1,149
Proceeds from sales of marketable securities and preferred stock	223	5,499
Maturities of short-term investments	14,350	7,250
Net cash used in investing activities	-1,185	-1,439
Financing activities
Principal repayment of borrowings	-5	-42
Proceeds from stock option exercises	222	25
Net cash provided by (used in) financing activities	9,517	-17
Proceeds from (Repayments of) Debt	10,000	0
Effect of Exchange Rate on Cash and Cash Equivalents	-9	0
Net decrease in cash and cash equivalents	58	-7,840
Cash and cash equivalents at beginning of period	36,855	35,723
Cash and cash equivalents at end of period	36,913	27,883
Non-cash investing and financing activities
Transfer of systems from property and equipment into inventory	48	54
Property and equipment costs incurred but not paid included in accounts payable	818	1,022
Supplemental cash flow disclosures
Cash paid for income taxes, net	17	8
Cash received for interest	109	284
Cash paid for interest	$73	$1

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation
	GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc, or Osmetech, as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, or the IPO, which was completed in June 2010. Immediately prior to the closing of the IPO, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of (i) the issuance of common stock of GenMark to the former shareholders of Osmetech and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a subsidiary controlled by GenMark, and the former shareholders of Osmetech received shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization. In September 2012, GenMark placed Osmetech into liquidation to simplify its corporate structure. The liquidation of Osmetech was completed in the fourth quarter of 2013.
	As the reorganization was deemed to be a transaction under common control, GenMark accounted for the reorganization in a manner similar to a pooling-of-interests. Once the reorganization became effective, all stock options granted under the Osmetech plc 2003 U.S. Equity Compensation Plan, long term incentive awards and all warrants issued by Osmetech were exchanged for options and warrants exercisable for common stock of the Company.
	Basis of Presentation
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and had an accumulated deficit of $272,341,000 as of March 31, 2015. Management expects operating losses to continue for the foreseeable future. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents and marketable securities as of March 31, 2015 were $71,712,000. The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the SEC on February 24, 2015. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts and share-based compensation. Actual results could differ from those estimates.
	Segment Information
	The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America.
	Reclassifications
	Costs previously reported as cost of revenue totaling $119,000 in the three months ended March 31, 2014 have been reclassified as general and administrative expenses to better align those costs with the functional areas that benefit from those expenditures. In addition, the Company also reclassified $198,000 included in other income and expense in 2014 into interest income to better align the true nature of the expenses. Reclassifications of prior year financial information have been made to conform to the current year presentation. None of the changes impacts the Company’s previously reported consolidated net revenue, earnings from operations, net earnings or net earnings per share.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial condition or results of operations upon adoption.
	In April 2015, the FASB issued Accounting Standards Update (ASU) 2015-03, Interest - Imputation of Interest. The standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability. The Company has retrospectively adopted this standard. The debt issuance costs have been recognized as a direct reduction to short and long term debt liability in the Condensed Consolidated Balance Sheets for all periods presented.
	In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company beginning in the first quarter of fiscal 2018 and allows for a full retrospective or a modified retrospective adoption approach. The Company is currently evaluating the impact of ASU 2014-09 on its consolidated financial statements.
	Cash and Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months.  Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
	Restricted Cash
	Restricted cash represents amounts designated for uses other than current operations and included $758,000 at March 31, 2015 held as security for the Company’s letter of credit with Banc of California.
	Receivables
	Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience.
	Product Warranties
	The Company generally offers a one-year warranty for its systems sold to customers and typically up to a sixty day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
	Intangible Assets
	Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
	Impairment of Long-Lived Assets
	The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows.
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to market value, as needed. This write down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
	Property and Equipment, net
	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset
	Income Taxes
	Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense.
	A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Compensation Related Costs [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	The Company recognizes stock-based compensation expense related to stock options, restricted stock awards, restricted stock units, and market-based stock units granted to employees and directors in exchange for services and employee stock purchases related to the Company's 2013 Employee Stock Purchase Plan, or the ESPP. Stock-based compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the award. Stock-based compensation expense is recorded in cost of sales, sales and marketing, research and development, and general and administration expenses based on the employee's respective function.
	The estimated fair value of stock options granted, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense on a straight-line basis to reflect vesting as it occurs. The expense is derived from the Black-Scholes Option Pricing Model that uses several judgment-based variables to calculate the expense. The inputs include the expected term of the stock option, the expected volatility and other factors.
	•	Expected Term. Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method.
	•	Expected Volatility. Expected volatility represents the volatility in the Company’s estimated stock price over the expected term of the stock option and is determined by review of the Company’s and similar companies’ historical experience.
	•	Expected Dividend. The Black-Scholes Option Pricing Model calls for a single expected dividend yield as an input. The Company assumed no dividends as it has never paid dividends and has no current plans to do so.
	•	Risk-Free Interest Rate. The risk-free interest rate used in the Black-Scholes Option Pricing Model is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option.
	The compensation expense related to the grant of restricted stock awards or units is calculated as the fair market value of the stock on the grant date as further adjusted to reflect expected forfeitures.
	Employee participation in the Company's 2010 Equity Incentive Plan, or the 2010 Plan, is at the discretion of the Compensation Committee of the Board of Directors of the Company. All stock options granted under the 2010 Plan are exercisable at a per share price equal to the closing quoted market price of a share of the Company’s stock on the NASDAQ Global Market on the grant date and generally vest over a period of between one and four years.
	Stock options are generally exercisable for a period of up to 10 years after grant and are typically forfeited if employment is terminated before the options vest. As of March 31, 2015, there were 282,659 shares available for future grant under the 2010 Plan. Each grant of stock options, restricted stock awards, restricted stock units and market-based stock units reduces the number of shares available for grant under the 2010 Plan.
	The following table summarizes stock option activity during the three months ended March 31, 2015:
		Number of		Weighted
		Shares		Average
				Exercise Price
	Outstanding at December 31, 2014	2,479,435		$	8.66
	Granted	747,950		$	13.17
	Exercised	-43,846		$	4.99
	Cancelled	-9,808		$	11.46
	Outstanding at March 31, 2015	3,173,731		$	9.77
	Vested and expected to vest at March 31, 2015	2,801,937		$	7.06
	Exercisable at March 31, 2015	1,486,655		$	7.06
	The weighted average fair value of stock options granted during the three months ended March 31, 2015 was $6.44. Options that were exercisable as of March 31, 2015 had a remaining weighted average contractual term of 6.09 years, and an aggregate intrinsic value of $8,844,383. As of March 31, 2015, there were 3,173,731 stock options outstanding, which had a remaining weighted average contractual term of 7.75 years and an aggregate intrinsic value of $10,419,803.
	Valuation of Stock-Based Awards
	The assumptions used in the valuation of stock-based awards for the periods ended March 31, 2015 and 2014 are summarized in the following table:
		Three Months Ended
		March 31,
		2015		2014
	Expected volatility (%)	50	%	70	%
	Expected life (years)	6.08		6.08
	Risk free interest rate (%)	1.69	%	1.82	%
	Expected dividend yield (%)	0	%	0	%
	In March 2013, the Company transitioned to granting restricted stock units under the 2010 Plan in lieu of granting restricted stock awards. The Company’s restricted stock award and restricted stock unit activity for the three months ended March 31, 2015 was as follows:
		Restricted Stock Awards				Restricted Stock Units
		Number of		Weighted		Number of	Weighted
		Shares		Average		Shares	Average
				Grant Date			Grant Date
				Fair Value			Fair Value
	Unvested at December 31, 2014	173,610		$	4.56	741,992	$	11.46
	Granted	—		$	—	522,396	$	13.17
	Vested	-43,389		$	4.34	-213,855	$	11.86
	Canceled or expired	-312		$	5.96	-4,868	$	12.1
	Unvested at March 31, 2015	129,909		$	4.63	1,045,665	$	12.23
	As of March 31, 2015, there was $511,993 of unrecognized compensation cost related to outstanding restricted stock awards, which is expected to be recognized over a weighted average period of 1.07 years. The total fair value of restricted stock awards that vested during the three months ended March 31, 2015 and 2014 was $561,256 and $1,746,771, respectively.
	As of March 31, 2015, there was $9,227,860 of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 3.18 years. The total fair value of restricted stock units that vested during the three months ended March 31, 2015 and 2014 was $2,708,096 and $726,430, respectively.
	Restricted stock awards or units may be granted at the discretion of the Compensation Committee of the Board of Directors under the 2010 Plan in connection with the hiring or retention of personnel and are subject to certain conditions. Restrictions expire at certain dates in accordance with specific provisions in the applicable award agreement. During the three months ended March 31, 2015 and 2014, stock-based compensation expense for restricted stock units and awards was $1,103,952 and $911,119, respectively.
	The Company issued 154,929 market-based restricted stock units in February 2015 which contain provisions to earn up to 200% of the target number of units. The fair value of market stock units was estimated on the date of grant using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of reaching the market condition based on simulated future stock prices, with the following assumptions: expected volatility of 44.7% and risk free interest rate of 1.1%. The vesting and issuance of Company stock depends on the Company's stock performance as compared to the Nasdaq Composite Index. The awards vest in three installments on December 31, 2015, December 31, 2016 and December 31, 2017 if stock performance metrics are achieved. At March 31, 2015, there was $2,626,984 of unrecognized stock-based compensation expense related to these awards, which is expected to be recognized over a weighted average period of 2.76 years. During the three months ended March 31, 2015 and 2014, stock-based compensation expense for market-based units was $172,585 and $0, respectively.
	The Company issued 43,200 performance-based restricted stock units in March 2014 with a grant date fair value of $12.30. The vesting and issuance of Company stock pursuant to these awards depends on obtaining regulatory clearance of various products within a defined time. Stock-based compensation expense for these performance-based awards is recognized when it is probable that the applicable performance criteria will be satisfied. The probability of achieving the relevant performance criteria is evaluated on a quarterly basis. At March 31, 2015, there was $398,520 of unrecognized stock-based compensation expense related to these awards.
	Employee Stock Purchase Plan
	Following the adoption of the ESPP by the Company’s Board of Directors in March 2013, the Company's stockholders approved the ESPP in May 2013 at the Company's Annual Meeting of Stockholders. A total of 650,000 shares of the Company’s common stock were originally reserved for issuance under the ESPP, which permits eligible employees to purchase common stock at a discount through payroll deductions.
	The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's Board of Directors; provided that no offering period may exceed 27 months. Employees may invest up to 10% of their gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of March 31, 2015, there were 528,142 shares of common stock available for issuance under the ESPP. Stock-based compensation expense related to the ESPP which is calculated using the Black-Scholes model at the beginning of each six-month offering period has been recorded during the three months ended March 31, 2015.

Net_Loss_per_Common_Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Common Share	Net Loss per Common Share
	Basic net loss per share is calculated by dividing loss available to stockholders of the Company's common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued, unless the effect would be anti-dilutive.
	The computations of diluted net loss per share for the three months ended March 31, 2015 and 2014 did not include the effects of the following stock options and restricted stock awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands).
		Three Months Ended March 31,
		2015	2014
	Options outstanding to purchase common stock	3,174	2,593
	Unvested restricted stock	1,363	1,127
	Total	4,537	3,720

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventory on hand as of March 31, 2015 and December 31, 2014 was comprised of the following (in thousands):
		March 31, 2015		December 31, 2014
	Raw materials	$	783	$	593
	Work-in-process	919		660
	Finished goods	446		884
		$	2,148	$	2,137

Property_and_Equipment_net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property and Equipment, net	Property and Equipment, net
	Property and equipment comprised the following as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015			December 31, 2014
	Property and equipment—at cost:
	Plant and machinery	$	7,815		$	6,737
	Instruments	6,366			6,611
	Office equipment	1,478			1,441
	Leasehold improvements	4,084			4,050
	Total property and equipment—at cost	19,743			18,839
	Less accumulated depreciation	(8,389		)	(7,787		)
	Property and equipment, net	$	11,354		$	11,052
	Depreciation expense was $733,000 and $516,000 for the three months ended March 31, 2015 and 2014, respectively.

Intangible_Assets_net

Intangible Assets, net	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net
	Intangible assets as of March 31, 2015 and December 31, 2014 were as follows (in thousands):
		March 31, 2015					December 31, 2014
		Gross carrying amount		Accumulated amortization	Net carrying amount		Gross carrying amount		Accumulated amortization	Net carrying amount
	Licensed intellectual property	$	2,750	-944	$	1,806	$	2,750	-880	$	1,870
	Intellectual property licenses have a weighted average remaining amortization period of 7.12 years as of March 31, 2015. Amortization expense for intangible assets for the three months ended March 31, 2015 and 2014 was $64,000 and $58,000, respectively. Estimated future amortization expense for these licenses (assuming no impairment charges) is as follows (in thousands):
	Fiscal Years Ending	Future Amortization Expense
	Remaining in 2015	$	193
	2016	254
	2017	254
	2018	254
	2019	254
	Thereafter	597
	Total	$	1,806

Loan_Payable

Loan Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Loan Payable	Loan Payable
	Long term debt consisted of the following (in thousands):
			31-Mar-15			31-Dec-14
	Term Loan A
	6.9% Principal		$	10,000		$	—
	Unamortized issuance discount		(704		)	—
	Total Debt, net		9,296			—
	Less current portion of long-term debt		206			—
	Long-Term Debt		$	9,502		$	—
	Term Loans
	In January 2015, the Company entered into a Loan and Security Agreement, or the Agreement, with General Electric Capital Corporation, or GECC, and certain other financial institutions party thereto, as lenders, pursuant to which the Company obtained (a) up to $35,000,000 in a series of term loans and (b) a revolving loan in the maximum amount of $5,000,000.  Under the terms of the Agreement, the Company may, subject to certain conditions, borrow:
	•	$10,000,000 on or before March 31, 2015 (“Term Loan A”);
	•	an additional $10,000,000 (“Term Loan B”), subject to the Company’s satisfaction of regulatory requirements necessary to CE Mark its ePlex™ system in Europe by a specified date; and
	•	an additional $15,000,000 (“Term Loan C,” and together with Term Loan A and Term Loan B, the “Term Loans”), subject to the Company’s satisfaction of FDA 510(k) market clearance for the sale of the Company’s ePlex™ system in the United States by a specified date.
	On March 27, 2015, the Company borrowed $10,000,000 pursuant to Term Loan A. The Term Loans will accrue interest at a rate equal to, a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum. The Company is only required to make interest payments on amounts borrowed pursuant to the Term Loans from the applicable funding date until March 1, 2017 (the “Interest Only Period”). Following the Interest Only Period, monthly installments of principal and interest under the Term Loans will be due until the original principal amount and applicable interest is fully repaid by January 12, 2019 (the “Maturity Date”).
	Under the Agreement, the Company is required to comply with certain affirmative and negative covenants, including, without limitation, delivering reports and notices relating to the Company’s financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, payments and acquisitions, other than as specifically permitted by the Agreement. As of March 31, 2015, the Company was in compliance with all covenants under the Agreement.
	Revolving Loan
	Pursuant to the Agreement, the Company may borrow up to $5,000,000 under the revolving loan facility. Borrowings under the revolving loan will accrue interest at a rate equal to (a) the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95% based on certain criteria as set forth in the Agreement. All principal and interest outstanding under the revolving loan is due and payable on the Maturity Date. Following the funding of Term Loan A, the Company is required to pay a commitment fee equal to 0.75% per annum of the amounts made available but unborrowed under the revolving loan. As of March 31, 2015, the Company had not borrowed any amounts pursuant the revolving loan facility.
	Debt Issuance Costs
	As of March 31, 2015 and December 31, 2014, the Company had $704,000 and $90,000, respectively, of unamortized debt issuance discount, which is offset against borrowings in long and short term debt.
	For the three months ended March 31, 2015, amortization of debt issuance costs was $49,000. Amortization of debt issuance costs was included in interest expense in our Unaudited Condensed Consolidated Statements of Comprehensive Loss for the periods presented.
	Letter of Credit
	In September 2012, the Company provided a $758,000 letter of credit issued by Banc of California to the landlord of its Carlsbad, California facility. This letter of credit was secured with $758,000 of restricted cash at March 31, 2015.

Leases

Leases	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Leases	Leases
	The Company has lease agreements for its office, manufacturing, warehousing and laboratory space and for office equipment. Rent and operating expenses charged under these arrangements were $300,000 and $295,000 for the three months ended March 31, 2015 and 2014, respectively. Pursuant to the Company's lease agreements, a portion of the monthly rent has been deferred. The balance of deferred rent as of March 31, 2015 and December 31, 2014 was $1,566,000 and $1,698,000, respectively. As of March 31, 2015, the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands):
	Fiscal Years Ending	Amount
	Remaining in 2015	$	817
	2016	1,116
	2017	1,123
	2018	1,156
	2019	1,191
	Thereafter	1,853
	Total minimum lease payments	$	7,256

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, such as cash equivalents, restricted cash, accounts receivable, and accounts payable approximate the related fair values due to the short-term maturities of these instruments.
	The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and
	the last unobservable, to measure fair value:
	• Level 1 — Quoted prices in active markets for identical assets or liabilities.
	• Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	• Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	22,054	$	—	$	—	$	22,054
	Corporate notes and bonds	—		21,035		—		21,035
	U.S. government and agency securities	—		10,759		—		10,759
	Commercial paper	—		2,247		—		2,247
		$	22,054	$	34,041	$	—	$	56,095
		December 31, 2014
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	31,412	$	—	$	—	$	31,412
	Corporate notes and bonds	—		18,387		—		18,387
	U.S. government and agency securities	—		15,264		—		15,264
		$	31,412	$	33,651	$	—	$	65,063
	Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

Investments

Investments	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments	Investments
	The following table summarizes the Company’s available-for-sale investments at March 31, 2015 and December 31, 2014 (in thousands):
	March 31, 2015		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	21,044		$	5	$	(14	)	$	21,035
	U.S. government and agency securities		10,758			2		(1		)	10,759
	Commercial paper		2,247			—		—			2,247
	Total		$	34,049		$	7	$	(15	)	$	34,041
	December 31, 2014		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	18,408		$	1	$	(22	)	$	18,387
	U.S. government and agency securities		15,267			2		(5		)	15,264
	Total		$	33,675		$	3	$	(27	)	$	33,651
	The following table summarizes the maturities of the Company’s available-for-sale securities at March 31, 2015 (in thousands):
		Amortized Cost			Estimated Fair Value
	Due in one year or less	$	31,799		$	31,790
	Due after one year through two years	2,250			2,251
	Total	$	34,049		$	34,041

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.
	As of March 31, 2015, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. Due to the Company's losses in the U.S. federal and state jurisdictions, it only records a tax provision or benefit related to minimum state tax payments or refunds in addition to foreign taxes.  Provision for income taxes was $22,000 and $6,000 for the three months ended March 31, 2015 and 2014, respectively.
	The Company is subject to taxation in the United States and in various state jurisdictions. As of March 31, 2015, the Company’s tax years from 2010 to 2012 are subject to examination by the United Kingdom tax authorities related to legacy operations. Except for net operating losses generated in prior years carrying forward to the current year, as of March 31, 2015, the Company is no longer subject to U.S. federal, state, local, or foreign examinations for years before 2010.

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and had an accumulated deficit of $272,341,000 as of March 31, 2015. Management expects operating losses to continue for the foreseeable future. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents and marketable securities as of March 31, 2015 were $71,712,000. The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the SEC on February 24, 2015. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period.
Segment Information	egment Information
	The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial condition or results of operations upon adoption.
Cash and Cash Equivalents	Cash and Cash Equivalents and Marketable Securities
Restricted Cash	Restricted Cash
	Restricted cash represents amounts designated for uses other than current operations and included $758,000 at March 31, 2015 held as security for the Company’s letter of credit with Banc of California
Receivables	Receivables
Use of Estimates
Product Warranties	Product Warranties
	The Company generally offers a one-year warranty for its systems sold to customers and typically up to a sixty day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
Intangible Assets	Intangible Assets
	Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
Inventories	Inventories
Property and Equipment, net	Property and Equipment, net
	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset
Income Taxes	Income Taxes
	Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense.
	A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Organization_and_Basis_of_Pres2

Organization and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Estimated useful lives of property and equipment	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Compensation Related Costs [Abstract]
Schedule of stock option activity	he following table summarizes stock option activity during the three months ended March 31, 2015:
		Number of		Weighted
		Shares		Average
				Exercise Price
	Outstanding at December 31, 2014	2,479,435		$	8.66
	Granted	747,950		$	13.17
	Exercised	-43,846		$	4.99
	Cancelled	-9,808		$	11.46
	Outstanding at March 31, 2015	3,173,731		$	9.77
	Vested and expected to vest at March 31, 2015	2,801,937		$	7.06
	Exercisable at March 31, 2015	1,486,655		$	7.06
Fair value assumptions of stock options	The assumptions used in the valuation of stock-based awards for the periods ended March 31, 2015 and 2014 are summarized in the following table:
		Three Months Ended
		March 31,
		2015		2014
	Expected volatility (%)	50	%	70	%
	Expected life (years)	6.08		6.08
	Risk free interest rate (%)	1.69	%	1.82	%
	Expected dividend yield (%)	0	%	0	%
Summary of restricted stock award and restricted stock units activity	The Company’s restricted stock award and restricted stock unit activity for the three months ended March 31, 2015 was as follows:
		Restricted Stock Awards				Restricted Stock Units
		Number of		Weighted		Number of	Weighted
		Shares		Average		Shares	Average
				Grant Date			Grant Date
				Fair Value			Fair Value
	Unvested at December 31, 2014	173,610		$	4.56	741,992	$	11.46
	Granted	—		$	—	522,396	$	13.17
	Vested	-43,389		$	4.34	-213,855	$	11.86
	Canceled or expired	-312		$	5.96	-4,868	$	12.1
	Unvested at March 31, 2015	129,909		$	4.63	1,045,665	$	12.23

Net_Loss_per_Common_Share_Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computations of diluted net loss per share	The computations of diluted net loss per share for the three months ended March 31, 2015 and 2014 did not include the effects of the following stock options and restricted stock awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands).
		Three Months Ended March 31,
		2015	2014
	Options outstanding to purchase common stock	3,174	2,593
	Unvested restricted stock	1,363	1,127
	Total	4,537	3,720

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Summary of inventory on hand	Inventory on hand as of March 31, 2015 and December 31, 2014 was comprised of the following (in thousands):
		March 31, 2015		December 31, 2014
	Raw materials	$	783	$	593
	Work-in-process	919		660
	Finished goods	446		884
		$	2,148	$	2,137

Property_and_Equipment_net_Tab

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property and equipment, net	Property and equipment comprised the following as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015			December 31, 2014
	Property and equipment—at cost:
	Plant and machinery	$	7,815		$	6,737
	Instruments	6,366			6,611
	Office equipment	1,478			1,441
	Leasehold improvements	4,084			4,050
	Total property and equipment—at cost	19,743			18,839
	Less accumulated depreciation	(8,389		)	(7,787		)
	Property and equipment, net	$	11,354		$	11,052

Intangible_Assets_net_Tables

Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of intangible assets	Intangible assets as of March 31, 2015 and December 31, 2014 were as follows (in thousands):
		March 31, 2015					December 31, 2014
		Gross carrying amount		Accumulated amortization	Net carrying amount		Gross carrying amount		Accumulated amortization	Net carrying amount
	Licensed intellectual property	$	2,750	-944	$	1,806	$	2,750	-880	$	1,870
Summary of estimated future amortization expense	Estimated future amortization expense for these licenses (assuming no impairment charges) is as follows (in thousands):
	Fiscal Years Ending	Future Amortization Expense
	Remaining in 2015	$	193
	2016	254
	2017	254
	2018	254
	2019	254
	Thereafter	597
	Total	$	1,806

Leases_Tables

Leases (Tables)	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Schedule of future minimum lease payments	As of March 31, 2015, the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands):
	Fiscal Years Ending	Amount
	Remaining in 2015	$	817
	2016	1,116
	2017	1,123
	2018	1,156
	2019	1,191
	Thereafter	1,853
	Total minimum lease payments	$	7,256

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Assets measured at fair value on a recurring basis	The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	22,054	$	—	$	—	$	22,054
	Corporate notes and bonds	—		21,035		—		21,035
	U.S. government and agency securities	—		10,759		—		10,759
	Commercial paper	—		2,247		—		2,247
		$	22,054	$	34,041	$	—	$	56,095
		December 31, 2014
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	31,412	$	—	$	—	$	31,412
	Corporate notes and bonds	—		18,387		—		18,387
	U.S. government and agency securities	—		15,264		—		15,264
		$	31,412	$	33,651	$	—	$	65,063

Investments_Tables

Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Company's available-for-sale investments	The following table summarizes the Company’s available-for-sale investments at March 31, 2015 and December 31, 2014 (in thousands):
	March 31, 2015		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	21,044		$	5	$	(14	)	$	21,035
	U.S. government and agency securities		10,758			2		(1		)	10,759
	Commercial paper		2,247			—		—			2,247
	Total		$	34,049		$	7	$	(15	)	$	34,041
	December 31, 2014		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	18,408		$	1	$	(22	)	$	18,387
	U.S. government and agency securities		15,267			2		(5		)	15,264
	Total		$	33,675		$	3	$	(27	)	$	33,651
Company's available-for-sale maturities investments	The following table summarizes the maturities of the Company’s available-for-sale securities at March 31, 2015 (in thousands):
		Amortized Cost			Estimated Fair Value
	Due in one year or less	$	31,799		$	31,790
	Due after one year through two years	2,250			2,251
	Total	$	34,049		$	34,041

Organization_and_Basis_of_Pres3

Organization and Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2015
Machinery and laboratory equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives of these assets	3 years
Machinery and laboratory equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives of these assets	5 years
Instruments [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives of these assets	4 years
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives of these assets	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset

Organization_and_Basis_of_Pres4

Organization and Basis of Presentation (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
	Segment
Property, Plant and Equipment [Line Items]
Accumulated deficit	($272,341,000)	($262,472,000)
Cash and cash equivalents	71,700,000
Sufficient capital to fund its operations	at least the next 12 months
Number of operating segment	1
Restricted cash	$758,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives of these assets	10 years
Systems [Member]
Property, Plant and Equipment [Line Items]
Products warranty period	1 year
Reagents [Member]
Property, Plant and Equipment [Line Items]
Products warranty period	60 days

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Compensation Related Costs [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,801,937
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$7.06
Schedule of stock option activity
Number of Share options Outstanding, Beginning Balance	2,479,435
Number of Share options, Granted	747,950
Number of Share options, Exercised	-43,846
Number of Share options, Cancelled	-9,808
Number of Share options Outstanding, Ending Balance	3,173,731
Number of Share options, Exercisable	1,486,655
Weighted average exercise price Outstanding, Beginning Balance	$8.66
Weighted average exercise price, Granted	$13.17
Weighted average exercise price, Exercised	$4.99
Weighted average exercise price, Cancelled	$11.46
Weighted average exercise price Outstanding, Ending Balance	$9.77
Weighted average exercise price, Exercisable	$7.06

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Options [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Options [Member]
Fair value of stock options granted
Expected volatility (%)	50.00%	70.00%
Expected life (years)	6 years 29 days	6 years 29 days
Risk free rate (%)	1.69%	1.82%
Expected dividend yield (%)	0.00%	0.00%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock Awards [Member]
Summary of restricted stock award and restricted stock units activity
Non-vested, Number of shares, Beginning balance	173,610
Number of shares, Granted	0
Number of shares, Vested	-43,389
Number of shares, Cancelled or expired	-312
Non-vested, Number of shares, Ending balance	129,909
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$4.56
Weighted Average Grant Date Fair Value, Granted	$0
Weighted average Grant Date Fair Value, Vested	$4.34
Weighted average Grant Date Fair Value, Cancelled or expired	$5.96
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$4.63
Restricted Stock Units [Member]
Summary of restricted stock award and restricted stock units activity
Non-vested, Number of shares, Beginning balance	741,992
Number of shares, Granted	522,396
Number of shares, Vested	-213,855
Number of shares, Cancelled or expired	-4,868
Non-vested, Number of shares, Ending balance	1,045,665
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$11.46
Weighted Average Grant Date Fair Value, Granted	$13.17
Weighted average Grant Date Fair Value, Vested	$11.86
Weighted average Grant Date Fair Value, Cancelled or expired	$12.10
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$12.23

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended			1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2013	Dec. 31, 2014
Share-based compensation (Textual) [Abstract]
Granted Stock option	747,950
Weighted average fair value of options granted	$6.44
Stock compensation expense	$2,339,000	$1,389,000
Options that are vested or expected to be vested	3,173,731
Weighted average contractual term	6 years 1 month 2 days
Option intrinsic value	8,844,383
Remaining weighted average contractual term	7 years 9 months
Aggregate intrinsic value of options exercisable	10,419,803
Weighted average exercise price of stock option	$13.17
Options [Member]
Share-based compensation (Textual) [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.69%	1.82%
Expected dividend yield	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	50.00%	70.00%
Restricted Stock Awards [Member]
Share-based compensation (Textual) [Abstract]
Total fair value of restricted stock vested	561,256	1,746,771
Stock compensation expense	1,103,952	911,000
Unrecognized compensation cost	511,993
Weighted average-period, cost is expected to be recognized	1 year 26 days
Weighted average fair value of options granted	$0
Vested restricted stock	43,389
Number of shares, Granted	0
Market Share Unit [Member]
Share-based compensation (Textual) [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.10%
Stock compensation expense	172,585	0
Unrecognized compensation cost	2,626,984
Weighted average-period, cost is expected to be recognized	2 years 279 days
Number of shares, Granted	154,929
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	45.00%
Restricted Stock Units [Member]
Share-based compensation (Textual) [Abstract]
Total fair value of restricted stock vested	2,708,096		726,430
Unrecognized compensation cost	9,228,000
Weighted average-period, cost is expected to be recognized	3 years 65 days
Weighted average fair value of options granted	$13.17
Vested restricted stock	213,855
Number of shares, Granted	522,396
Performance Shares [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost	$398,520
Weighted average fair value of options granted	$12.30
Number of shares, Granted	43,200
Options [Member]
Employee Stock Purchase Plan [Abstract]
Maximum offering period	27 months
2010 Plan [Member]
Share-based compensation (Textual) [Abstract]
Future grant of awards under the Plan	282,659
2010 Plan [Member] | Minimum [Member]
Share-based compensation (Textual) [Abstract]
Options vested	1 year
2010 Plan [Member] | Maximum [Member]
Share-based compensation (Textual) [Abstract]
Options vested	4 years
2010 Plan [Member] | Options [Member]
Share-based compensation (Textual) [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
2013 Employee Stock Purchase Plan [Member] | Options [Member]
Employee Stock Purchase Plan [Abstract]
Common stock reserved for future issuance	528,142				650,000
Purchase price as a percent of the fair market value of the common stock				85.00%
Maximum offering period				6 months
Maximum employee investment in ESPP as a percentage of gross compensation				10.00%
Maximum shares of common stock that can be puchased by each employee				1,500

Net_Loss_per_Common_Share_Deta

Net Loss per Common Share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	4,537	3,720
Options [Member]
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	3,174	2,593
Unvested restricted stock [Member]
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	1,363	1,127

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of inventory on hand
Raw materials	$783	$593
Work-in-process	919	660
Finished goods	446	884
Total	$2,148	$2,137

Property_and_Equipment_net_Det

Property and Equipment, net (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property and equipment-at cost:
Total property and equipment-at cost	$19,743		$18,839
Less accumulated depreciation	-8,389		-7,787
Property and equipment, net	11,354		11,052
Depreciation expense	733	516
Plant and machinery [Member]
Property and equipment-at cost:
Total property and equipment-at cost	7,815		6,737
Instruments [Member]
Property and equipment-at cost:
Total property and equipment-at cost	6,366		6,611
Office equipment [Member]
Property and equipment-at cost:
Total property and equipment-at cost	1,478		1,441
Leasehold improvements [Member]
Property and equipment-at cost:
Total property and equipment-at cost	$4,084		$4,050

Intangible_Assets_net_Details

Intangible Assets, net (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of intangible assets
Net carrying amount	$1,806
Licensed intellectual property [Member]
Summary of intangible assets
Gross carrying amount	2,750	2,750
Accumulated amortization	-944	-880
Net carrying amount	$1,806	$1,870

Intangible_Assets_net_Details_

Intangible Assets, net (Details 1) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Summary of estimated future amortization expense
Remaining in 2015	$193
2015	254
2016	254
2017	254
2018	254
Thereafter	597
Net carrying amount	$1,806

Intangible_Assets_net_Details_1

Intangible Assets, net (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Amortization expense for intangible assets	$64	$58
Licensed intellectual property [Member]
Indefinite-lived Intangible Assets [Line Items]
Weighted average amortization period	7 years 1 month 13 days

Loan_Payable_Details_Textual

Loan Payable (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2015
Loan Payable (Textual) [Abstract]
Restricted cash		$758,000
New Letter of Credit [Member] | Letter of Credit [Member]
Loan Payable (Textual) [Abstract]
Increased amount of line of credit availability	758,000
Banc of California [Member] | New Letter of Credit [Member] | Letter of Credit [Member]
Loan Payable (Textual) [Abstract]
Restricted cash		$758,000

Leases_Details

Leases (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Schedule of future minimum lease payments
Remaining in 2015	$817
2015	1,116
2016	1,123
2017	1,156
2018	1,191
Thereafter	1,853
Total future minimum payments	$7,256

Leases_Details_Textual

Leases (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Leases [Abstract]
Rent and operating expenses	$300	$295
Operating lease, deferred expense	$1,566		$1,698

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Assets:
Assets, fair value	$56,095	$65,063
Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Assets, fair value	22,054	31,412
Significant Other Observable Inputs (Level 2) [Member]
Assets:
Assets, fair value	34,041	33,651
Significant Unobservable Inputs (Level 3) [Member]
Assets:
Assets, fair value	0	0
Money market funds (cash equivalents) [Member]
Assets:
Assets, fair value	22,054	31,412
Money market funds (cash equivalents) [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Assets, fair value	22,054	31,412
Money market funds (cash equivalents) [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Assets, fair value	0	0
Money market funds (cash equivalents) [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets:
Assets, fair value	0	0
Corporate notes and bonds [Member]
Assets:
Assets, fair value	21,035	18,387
Corporate notes and bonds [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Assets, fair value	0	0
Corporate notes and bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Assets, fair value	21,035	18,387
Corporate notes and bonds [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets:
Assets, fair value	0	0
U.S. government and agency securities [Member]
Assets:
Assets, fair value	10,759	15,264
U.S. government and agency securities [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Assets, fair value	0	0
U.S. government and agency securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Assets, fair value	10,759	15,264
U.S. government and agency securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets:
Assets, fair value	0	0
Commercial paper [Member]
Assets:
Assets, fair value	2,247
Commercial paper [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Assets, fair value	0
Commercial paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Assets, fair value	2,247
Commercial paper [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets:
Assets, fair value	$0

Investments_Details

Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Company's available-for-sales investments
Amortized Cost	$34,049	$33,675
Gross Unrealized Gains	7	3
Gross Unrealized Losses	-15	-27
Fair Value	34,041	33,651
Corporate notes and bonds [Member]
Company's available-for-sales investments
Amortized Cost	21,044	18,408
Gross Unrealized Gains	5	1
Gross Unrealized Losses	-14	-22
Fair Value	21,035	18,387
U.S. government and agency securities [Member]
Company's available-for-sales investments
Amortized Cost	10,758	15,267
Gross Unrealized Gains	2	2
Gross Unrealized Losses	-1	-5
Fair Value	10,759	15,264
Commercial paper [Member]
Company's available-for-sales investments
Amortized Cost	2,247
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	$2,247

Investments_Details_1

Investments (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Company's available-for-sales investments
Less than 1 year, Amortized cost	$31,799
Due in 1 to 2 years, Amortized cost	2,250
Amortized Cost	34,049	33,675
Less than 1 year, Fair value	31,790
Due in 1 to 2 years, Fair value	2,251
Fair Value	$34,041	$33,651

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes	$22,000	$6,000
Total amount of unrecognized tax benefits	$0		$0